CIK cell therapy

Cytokine-induced killer (CIK) cell therapy

In addition to allogeneic transplantation, we offer immunological treatment concepts for high-risk patients with expected relapse of leukemia or myelodysplastic syndrome. As the only center in Germany we perform treatment with cytokine-induced killer (CIK) cells, a treatment which we have completely redeveloped and optimized in recent years.

CIK cells are a heterogeneous immune cell population of T lymphocytes and natural killer (NK) cells. CIK cells can be generated from mononuclear cells of the original stem cell donor in just 10-12 days. Since March 24, 2016, we offer a multicenter Phase I / II study (EudraCT Number: 2013-005446-11) titled "Preemptive Immunotherapy with IL-15 Activated Cytokine-Induced Killer Cells (CIK Cells) for Relapse Prevention in High-Risk Patients with Acute Leukemia and myelodysplastic